<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498952</url>
  </required_header>
  <id_info>
    <org_study_id>CD-ON-MEDI-573-1028</org_study_id>
    <nct_id>NCT01498952</nct_id>
  </id_info>
  <brief_title>MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.</brief_title>
  <acronym>MEDI-573-1028</acronym>
  <official_title>A Phase 1b/2, Open-label, Randomized Study of MEDI-573 in Combination With Sorafenib Verses Sorafenib Alone in Adult Subjects With Unresectable or Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard
      of care in adult subjects with unresectable or metastatic HCC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: (Dose Evaluation Phase): Safety and Tolerability of 2 Dose Levels of MEDI-573 Combined with Standard of Care (SOC)</measure>
    <time_frame>6 Months</time_frame>
    <description>The primary objective of the dose-evaluation phase of this study (Phase 1b) is to evaluate the safety and tolerability of MEDI-573 in combination with SOC in subjects with unresectable or metastatic HCC. This will be measured by the number of adverse events, serious adverse events, and laboratory changes from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of MEDI-573</measure>
    <time_frame>19 Months</time_frame>
    <description>To describe the pharmacokinetics (PK) of MEDI-573 in combination with SOC in the Phase 1b and Phase 2 portions of this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MEDI-573</measure>
    <time_frame>19 Months</time_frame>
    <description>To determine the immunogenicity (IM) of MEDI-573 in combination with SOC in the Phase 1b and Phase 2 portions of this study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Unresectable or Metastatic Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-573 Dose 1 plus Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-573 Dose 2 plus Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-573 Dose 2 plus sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-573 (1 of 3 doses)</intervention_name>
    <description>MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years or minimum age of consent per local regulations at the time of
             screening

          -  Unresectable or metastatic hepatocellular carcinoma

          -  ECOG Performance Status ≤ 2

          -  Life expectancy of ≥ 3 months;

        Exclusion Criteria:

          -  Child-Pugh Score for Cirrhosis Mortality &gt; 7 points

          -  Prior or current system anti-cancer therapy for HCC, including cytotoxic, biologic,
             targeted or experimental therapy

          -  Prior local treatment for HCC less than 4 weeks prior to initiating study treatment

          -  Active second malignancy

          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks prior to
             initiating study treatment

          -  Thrombotic or embolic events within 6 months prior to initiating study treatment

          -  Ongoing pancreatitis

          -  Uncontrolled or refractory ascites

          -  Evidence of ongoing spinal cord compression, known carcinomatous meningitis, or known
             leptomeningeal carcinomatosis

          -  Hepatic encephalopathy &gt; Grade 1

          -  Active brain metastases with exceptions

          -  Poorly controlled diabetes mellitus

          -  Active coronary artery disease

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Perez, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Golden Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>November 26, 2013</last_update_submitted>
  <last_update_submitted_qc>November 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC, liver cancer, hepatocellular carcinoma, MEDI-573, anti-IGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

